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Abstract
Background & Aims: Since acute hepatitis C virus (HCV) infection is often asymptomatic, it is difficult to examine the rate
and determinants of spontaneous clearance. Consequently, these studies are subject to bias, which can potentially lead to
biased rates of viral clearance and risk estimates. We evaluated determinants of spontaneous HCV clearance among HCV
seroconverters identified in a unique community-based cohort.
Methods: Subjects were 106 drug users with documented dates of HCV seroconversion from the Amsterdam Cohort Study.
Logistic regression was used to examine sociodemographic, behavioral, clinical, viral and host determinants, measured
around acute infection, of HCV clearance.
Results: The spontaneous viral clearance rate was 33.0% (95% confidence interval (CI) 24.2–42.8). In univariate analyses
female sex and fever were significantly associated with spontaneous clearance. The favorable genotypes for rs12979860
(CC) and rs8099917 (TT) were associated with spontaneous clearance, although borderline significant. In multivariate
analysis, females with the favorable genotype for rs12979860 (CC) had an increased odds to spontaneously clear HCV
infection (adjustedOR 6.62, 95% 2.69–26.13), whereas females with the unfavorable genotype were as likely as men with the
favorable and unfavorable genotype to clear HCV. Chronic Hepatitis B infection and absence of HIV coinfection around HCV
seroconversion also favor HCV clearance.
Conclusions: This study shows that co-infection with HIV and HBV and genetic variation in the IL28B region play an
important role in spontaneous clearance of HCV. Our findings suggest a possible synergistic interaction between female sex
and IL28B in spontaneous clearance of HCV.
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Introduction
Hepatitis C virus (HCV) is mainly transmitted through exposure
to infected blood [1]. Acute infection is usually asymptomatic and
can lead to chronic infection in an estimated 75% of individuals
[2,3]. Chronic HCV infection can in time lead to liver fibrosis and
cirrhosis, end-stage liver disease, and hepatocellular carcinoma [4].
Treatment success rates are higher when individuals are treated
during acute HCV than when they are treated during chronic
infection [5–7]. To be able to decide whether early treatment is
indicated, early predictors of spontaneous viral clearance are
urgently needed.
The majority of the studies on spontaneous viral clearance have
been conducted among anti-HCV positive individuals, for whom
the exact moment of anti-HCV seroconversion is unknown. These
prevalence studies are subject to selection bias, which can
potentially lead to biased rates of viral clearance and risk estimates
[8]. Studies among acute HCV cases are less likely to suffer from
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and determinants of spontaneous viral clearance of acute HCV
infection is restricted, since acute infection is usually asymptomatic
and therefore rarely recognized. The limited published data
indicated that 14–42% of persons with acute HCV cleared the
virus, and that clearance is associated with symptomatic acute
HCV, female sex, non-black race, lower peak HCV-RNA titer,
induction of neutralizing antibodies early in HCV infection, and
high and broad HCV-specific CD4
+ and CD8
+ T-cell responses
[7,9–17]. Recently, several studies demonstrated that genetic
variations in the region near the interleukin-28B (IL28B) are
associated with HCV treatment response [18–21]. IL 28B gene
encodes interferon (IFN)-l3, which is related to IFN-a and IFN-b.
Two single nucleotide polymorphisms (SNPs), rs12979860 and
rs8099917, located upstream of the IL28B gene have also been
associated with spontaneous clearance [19,22–25]. Although the
sample size in some of these studies is not limited, all but one [24]
have been conducted among individuals with prevalent HCV
infection [19,22,25] or in a selected subgroup [23] and lack precise
longitudinal data around HCV seroconversion.
Since the prospective Amsterdam Cohort Study (ACS) among
drug users (DU) has retrospectively identified a substantial number
of incident HCV infections [26] it provided a unique opportunity
to study the spontaneous HCV clearance rate and its potential
sociodemographic, behavioral, clinical, viral and host determi-
nants (including coinfections), measured before and around acute
HCV infection, in a population that includes asymptomatic acute
HCV cases.
Methods
Ethics statement
The medical ethics committee of the Academic Medical Center
(MEC AMC) approved the current study.
Study population
The ACS among DU is an open, prospective cohort study
initiated in 1985 to investigate the prevalence, incidence, and risk
factors of human immunodeficiency virus (HIV) infections and
other blood-borne and/or sexually transmitted diseases, as well as
the effects of interventions [27]. All ACS participants provide
written informed consent. ACS participants visit the Amsterdam
Health Service every 4–6 months; they complete a standardized
questionnaire about their health, risk behavior, and sociodemo-
graphic situation. Questions at ACS entry refer to the 6 months
preceding the visit; questions at follow-up refer to the interim since
the preceding visit. Blood is drawn each visit for laboratory testing
and storage.
Screening for HCV, HBV and HIV
To identify HCV seroconverters, we retrospectively tested stored
serum from all participants having at least two visits between
December 1985 and November 2005 (n=1276). Individuals who
were anti-HCV negative at ACS entry were tested for antibodies at
their most recent ACS visit. On finding seroconversion, we tested
samples taken between these two visits to determine the moment of
seroconversion (third generation commercial microparticle EIA
system, AxSym HCV version 3.0; Abbott, Wiesbaden, Germany).
All HCV seroconverters were included in the present study (n=59).
Also included, were DU who were anti-HCV positive at ACS entry
and had started injecting drug use within 2 years before entry. Since
we have shown that approximately 50% of DU acquire HCV
infection within 2 years after starting injecting drug use [26], the
latter group most likely represent recent HCV infections.
To assess hepatitis B status, stored blood samples were
retrospectively tested for anti-HBc (AxSym Core, Abbott,
Germany and Hepanostika; Organon Technika, the Netherlands)
by the same algorithm as for HCV. To identify individuals with an
active hepatitis B virus (HBV) infection, the presence of HBV
surface antigen (HBsAg) was determined (AxSym HBsAg, Abbott,
Germany) in serum. All ACS participants (n=1,640) were
prospectively tested for HIV antibodies by enzyme linked
immunosorbent assays (ELISA) at each visit. Results since 1986
have been confirmed by Western blot using HIV Blot version 2.2,
Genelab diagnostics (Singapore).
Reverse-transcription polymerase chain reaction (RT-PCR)
methods
For each seroconverter, HCV RNA was measured at a
minimum of 4 time-points when samples were available: the last
visit before HCV seroconversion, i.e., the last anti-HCV negative
visit, two visits shortly after HCV seroconversion and a visit
approximately 1 year after HCV seroconversion. In those who
were anti-HCV positive at entry, HCV RNA was measured at, at
least, 2 time-points: at study entry and the consecutive visit(s). All
serum samples were tested for the presence of HCV RNA using an
in-house quantitative real-time RT-PCR based on the conserved
59-UTR, and HCV genotyping was performed as described by
Van de Laar et al. [28] The nucleotide sequence data have been
deposited in the GenBank sequence database under accession
numbers JN547478-JN547481 and JN657313 t/m JN657415.
Il28B genotyping
Single nucleotide polymorphism (SNP) genotyping was
performed using Allelic Discrimination assays from Applied
Biosystems for the SNPs rs8099917 and rs12979860 following
the instructions of the manufacturer. Genotyping for rs8099917
was performed using predesigned assays (Applied Biosystems,
assay ID ‘‘C__11710096_10’’).
Genotyping for rs12979860 was performed using Taqman
custom-designed primers and probes as follows: forward primer
GCCTGTCGTGTACTGAACCA, reverse primer GCGCGGA-
GTGCAATTCAAC, and probes TGGTTCGCGCCTTC (VIC)
and CTGGTTCACGCCTTC (FAM) (Applied Biosystems).
Before performing the PCR reactions DNA is added with Allelic
Discrimination Assay Mix and TaqMan Universal PCR Master
Mix to MicroAmp Optical 96-Well Reaction Plates (Applied
Biosystems). Real-Time PCR reactions were performed using the
ABI Prism 7900HT system (Applied Biosystems). After preheating
for 10 min. at 95uC, 40 cycles of 15 seconds at 95uC and one
minute at 60uC followed. Data were analyzed using the ABI
PRISM SDS software v.2.2.1 (Applied Biosystems).
Statistical analyses and definitions
Date of HCV seroconversion was estimated as the midpoint
between the last anti-HCV negative visit and the first anti-HCV
positive visit in HCV seroconverters. In recent HCV cases who
started injection #2 years prior to enrolment, the date of
seroconversion was estimated as the midpoint between start of
injection drug use and entry in ACS. In the group of HCV
seroconverters, spontaneous HCV clearance was defined as 2
consecutive HCV RNA-negative test results, at least 4 months
apart, after HCV seroconversion. In the group with recent HCV
infection, clearance was defined as 2 consecutive HCV RNA-
negative test results after ACS entry. HCV viral persistence is
defined as the continuous presence of HCV RNA at one or two of
these visits.
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between spontaneous clearance of HCV and sociodemographic
variables at the first anti-HCV positive visit: drug use related
variables, standard collected data on clinical symptoms, HCV
characteristics at first visit after seroconversion or study entry,
co-infections and IL28B (rs12979860 and rs8099917). Multivariate
logistic regression models were built using backward stepwise
techniques. All variables with a p-value#0.20 in univariate analysis
were considered for entry into the model. Statistical analysis was
performed by use of STATA (version 11.1; StataCorp) and SPSS
(version 17.0; SPSS Inc.) software. A p-value#0.05 was considered
to be statistically significant. Interaction and confounding were
checked between the variables in the final models.
Furthermore, using Poisson regression, we examined whether
the incidence of each clinical symptom reported at visits up to 2
years following HCV seroconversion was higher for DU who
cleared HCV after acute infection compared with those who did
not. For the HCV seroconverters, we used the last visit before
HCV seroconversion and the first 3 visits following HCV
seroconversion for these analyses. Since DU could contribute
more visits and events, Generalized Estimating Equations (GEE)
was used to correct for repeated measurements within subjects.
In a sensitivity analysis, analyses were repeated using only the
HCV seroconverters who had a small seroconversion interval (i.e.,
no more than 6 months between last anti-HCV negative visit and
first anti-HCV positive visit) (n=36).
Results
General characteristics
Sufficient follow-up and serum were available to assess outcome
of acute HCV infection for 55 out of 59 HCV seroconverters and
for 51 of 58 recent HCV infected DU. The median interval
between last negative and first positive visit was 4.0 months
(interquartile range (IQR) 3.7–5.0 months) for the 55 HCV
seroconverters. The median duration of injecting drug use before
study entry for DU with recent HCV infection was 1.12 years
(IQR 0.33–1.50 years). Of all 106 participants, 41.5% were
female, and the majority was of west-European ethnicity (84.9%).
The median age at HCV seroconversion was 28.5 years (IQR
24.7–34.2 years). Of 106 participants, 93 (87.7%) reported recent
injecting drug use, of whom 50.5% reported daily injecting and
34.6% reported recent sharing of needles. None of the 106
participants received HCV treatment in the first two years
following HCV seroconversion.
Of those that were HCV-RNA-positive around HCV serocon-
version or ACS entry, 42.5% had HCV genotype 1, 35.0% had
genotype 3, 7.5% had genotype 2, and 7.5% had genotype 4. For
the 6 samples in which HCV genotype could not be determined,
HCV viral load was ,1,000 IU/ml. The median log viral load
(IQR) at the first available visit after seroconversion or ACS entry
did not differ significantly among genotypes (p=0.25, Kruskal-
Wallis) being 4.40 (3.38–5.42), 5.73 (4.64–6.14), 4.36 (3.19–5.30)
and 4.69 (3.00–5.66) for genotypes 1, 2, 3, and 4, respectively.
Median baseline alanine aminotransferase (ALT) levels for those
who developed cHCV was 31.0 IU/L (IQR 17.3–89.5) and
12.0 IU/L (IQR 7.50–29.0) for those who spontaneously resolved
HCV, p=0.002 [29].
Rate and determinants of spontaneous viral clearance. Ac-
cording to our definition of at least 2 consecutive HCV-RNA
negative test results shortly after HCV seroconversion, the infection
was spontaneously cleared in 35 of the 106 DU (33.0%, 95% CI
24.2–42.8%).
Sociodemographics and behavior. In univariate analysis,
women had threefold higher odds of spontaneous viral clearance
(see table 1) than men. Of 38 HIV-negative women, 50.0%
cleared HCV spontaneously, in contrast to only 25.5% of HIV-
negative men. Having a steady partner who injected or did not
inject, was also significantly associated with higher odds of HCV
clearance compared to not having a steady partner (twofold and
threefold higher odds, respectively).
Clinical symptoms. Of all HCV cases, 36.8% reported at
least one of the clinical symptoms (jaundice, severe tiredness, fever,
night-sweating, diarrhea) in the 4–6 months preceding the first
anti-HCV positive visit, but except for fever, none of the examined
symptoms were significantly associated with HCV viral clearance
in univariate analysis (table 1). DU who reported fever were more
likely to clear HCV than those who did not (OR 4.00, 95% CI
1.08–14.76). This association was borderline significant after
adjustment for sex (adjusted OR (aOR) 3.80, 95% CI 0.99–14.61).
To further evaluate the association between viral clearance and
clinical symptoms that might have occurred around the time of
HCV seroconversion, we determined the incidence rate ratios of
clinical symptoms on different visits shortly before and following
HCV seroconversion (see methods section). In line with logistic
regression analysis, the incidence rate of each of symptom did not
significantly differ between those individuals who spontaneously
cleared HCV and those individuals who developed chronic
infection, except for fever (data not shown).
Co-infections. At the time of HCV seroconversion (or ACS
entry in those already HCV-positive), 13 DU were HIV-co-
infected. In univariate analysis, spontaneous HCV clearance was
more likely in HIV-negative individuals than in HIV-positive
individuals (OR 3.03, 95% CI 0.63–14.51), although the
difference did not reach statistical significance, P=0.13 (table 2).
The effect of HIV co-infection did not change after adjusting for
sex (aOR 3.48, 95% CI 0.70–17.40). CD4 and CD8 T-cell counts
were available for 51 of the 106 HCV seroconverters and only 1
DU had a CD4 count below 350 cells/mL. The median CD4 and
CD8 count did not differ between participants who cleared HCV
and those who developed chronic HCV infection 935 (IQR 710–
1,180) and 990 (IQR 770–1,180) CD4
+ cells/mL, and 60 (IQR
45–85) and 70 (IQR 40–70) CD8
+ cells/mL, respectively). For
those with detectable HCV viral load at the first available sample
after ACS entry or HCV seroconversion and who developed
persistent viremia, HCV viral load tended to be lower in women
than in men, but this effect was not statistically significant (median
log 3.43 copies/mL (IQR 3.00–4.70) and 4.36 copies/mL (IQR
3.00–5.43), respectively (P=0.14).
Of all patients with acute HCV, 27 had evidence of cleared
HBV infection, (i.e., they were anti-HBc-positive and HBsAg-
negative), and 8 had a chronic HBV infection (i.e., were HBsAg-
positive and anti-HBc-positive). In univariate analysis, those with
chronic HBV infection were more likely to clear HCV
spontaneously (OR 6.00, 95% CI 1.12–32.1) than those never
exposed (P=0.04). After adjusting for sex, those with chronic
HBV infection were still more likely to clear HCV spontaneously,
although this effect was borderline significant. (aOR 5.00, 95% CI
0.88–28.36), P=0.07.
Il28 B genotypes and spontaneous viral clearance. Data
on both SNPs, rs8099917 and rs12979860, was available for 100/
106 participants. Allele frequencies of both SNPs were comparable
to those reported elsewhere in Europe [19,22], rs8099917
(T=0.84, G=0.16) and rs12979860 (C=0.70, T=0.30). The
CC genotype frequency of rs12979860 were comparable between
males (CC=0.55) and females (CC=0.49). For rs8099917 the TT
genotype frequency was also comparable for males (TT=0.66)
Gender and IL28B Predict Spontaneous HCV Clearance
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rs8099917 and the CC genotype of rs12979860 were more likely
to have cleared the virus than those with the GG/TG and TT/CT
genotype respectively (rs8099917 OR 2.36, 95% CI 0.85–6.54,
rs12979860 OR 3.55, 95% CI 0.95–5.45), although the effects
were borderline significant (table 2). Since female sex is a strong
predictor for spontaneous clearance, we examined the effect of sex
on clearance separately for each Il28B genotype and their alleles
(figure 1). Women were 2.3 times more likely to clear HCV than
men with the favorable genotype for rs12979860 (female/male
clearance ratio 2.31 (28.2%/12.2%)). Whereas this ratio for the
unfavorable TT/CT genotype was 1.39 (13.5/9.7), suggesting an
interaction between sex and rs12979860. This interaction was not
found for rs8099917 (TT 1.72 (23.5%/13.7%), GT/GG 1.89
(13.3%/6.7%)).
Next, we investigated the interaction between sex and each SNP
in a logistic regression model. We found a potential interac-
tion between rs12979860 and sex. Males with the favorable CC
genotype had a somewhat increased odds to spontaneous clear
HCV (OR 1.58, 95% CI 0.46–5.44) as compared to the reference
group (males without the favorable CC genotype), although this
effect was not significant. Females without the favorable CC
genotype were as likely as men with the favorable genotype to
spontaneously clear HCV (OR 1.58, 95% CI 0.43–6.10).
Interestingly, females with the favorable CC genotype had an
increased odds to spontaneous clear HCV of OR 7.20 (95% CI
1.87–27.75) as compared to the reference group, overall P=0.015.
Multivariate analysis. Because of the interaction of
rs12979860 and sex we used the combined variable in our final
multivariate analyses. Females with CC genotype for rs12979860
had increased odds to spontaneously clear HCV infection (aOR
6.62, 95% CI 2.69–26.13) when compared to males without the
favorable genotype (table 3). Males with the favorable genotype
and females without the unfavorable genotype had comparable
risks as men with the unfavorable genotype to clear the virus.
Those who reported fever in the period preceding the first anti-
HCV positive visit were also more likely to spontaneously
clear HCV infection (OR 5.03, 95% CI 1.24–20.33). Further
Table 1. Univariate analysis of sociodemographic factors, behavioral factors and clinical symptoms associated with HCV clearance
in a cohort of 106 individuals with acute HCV acquired through injection drug use.
N Clearance rate (%) OR (95%CI) P value
Age (per 10 year increase) 106 33.0 0.62 (0.32–1.18) 0.13
Sex Male 62 22.6 1 0.007
Female 44 47.7 3.13
Ethnicity Western European 90 31.1 1 0.33
Non-Western European 16 43.8 1.72 (0.58–5.09)
Calendar year of infection #1988 43 30.2 1 0.63
1989–1991 25 44.0 1.81 (0.65–5.04)
1992–1994 21 28.6 0.92 (0.29–2.91)
$1995 17 29.4 0.96 (0.28–3.29)
Jaundice No 32 31.3 1 0.97
Yes 9 33.3 1.10 (0.23–5.31)
Unknown 65 33.9 1.13 (0.45–2.79)
Severe tiredness No 77 35.1 1 0.69
Yes 26 30.8 0.82 (0.32–2.14)
Fever No 92 30.4 1 0.033
Yes 11 63.6 4.00 (1.08–14.76)
Night-sweating No 77 35.1 1 0.69
Yes 26 30.8 0.82 (0.32–2.14)
Diarrhea No 100 34.0 1 0.98
Yes 3 33.3 0.97 (0.09–11.09)
Having a steady partner that inject drugs No steady partner 66 24.2 1 0.033
Steady partner who injected drugs now or ever 14 42.9 2.34 (0.71–7.77)
Steady partner who never injected drugs 25 52.0 3.39 (1.28–8.89)
Injecting drug use in the previous 6 months No 13 38.5 1 0.66
Yes 93 32.3 0.76 (0.23–2.53)
Continuation of injecting drug use after HCV
seroconversion (i.e., injecting drug use at first
and second anti-HCV positive visit)
No 32 34.4 1 0.77
Yes 73 31.5 0.88 (0.36–2.12)
Alcohol use (any consumption in the
previous 6 months)
No 18 38.6 1 0.60
Yes 88 29.0 0.74 (0.24–2.28)
doi:10.1371/journal.pone.0027555.t001
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change these results. Absence of HIV and presence of a chronic
HBV infection were still borderline associated with viral clearance
in this multivariate model, resp. (aOR 6.32, 95% CI 0.86–46.25)
and (aOR 8.72, 95% CI 0.99–76.37).
In a sensitivity analysis including only HCV seroconverters with
a seroconversion interval #6 months (n=36), the results for the
interaction rs12979860/sex and fever were comparable to the
results from the multivariate model. The rate of spontaneous
clearance was 36.1% (95% CI 20.3–52.3%). In an additional
analysis including only West-Europeans (n=86), females with
the favourable CC genotype for rs12979860 had an increased odd
to spontaneously clear their HCV infection (aOR 5.17, 95% CI
1.21–22.13) as compared to males without the favourable
genotype.
Discussion
In this study, the clearance rate and factors influencing
spontaneous HCV clearance were assessed in a prospective cohort
of retrospectively identified DU with acute HCV, regardless of
their clinical presentation at the time of acute HCV infection. To
our knowledge, this is one the largest longitudinal studies on
factors associated with spontaneous HCV clearance in individuals
with drug-use-related acute HCV infection. The rate of sponta-
neous HCV clearance was 33.0%. Our main finding is that
women with the favorable genotype for rs12989760 were more
Table 2. Univariate analysis of host genetic factors and viral coinfections associated with HCV clearance in a cohort of 106
individuals with acute HCV acquired through injection drug use.
N Clearance rate (%) OR (95%CI) P value
HCV genotype 1 34 11.9 1 0.34
26 0 . 0 -
3 28 14.3 1.25 (0.28–5.53)
4 6 16.7 1.50 (0.14–16.32)
Untypable (due to low viral load) 6 50.0 7.15 (1.11–50.66)
Log HCV viral load #3 19 26.3 8.93 (0.95–84.30) 0.12
3–4.9 26 3.9 1
$4.9 27 11.1 3.13 (0.30–32.20)
HIV-1 Presence of HIV-1 antibodies 13 15.4 1 0.13
Absence of HIV-1 antibodies 93 35.5 3.03 (0.63–14.47)
HBV co-infection Anti-HBc-negative, HBsAg-negative 69 33.3 1 0.025
Anti-HBc-positive, HBsAg-negative 27 19.2 0.48 (0.16–1.43)
Anti-HBc-positive, HBsAg-positive 8 75.0 6.00 (1.12–32.09)
rs8099917 GG/TG 30 20.0 1 0.084
TT 70 37.1 2.36 (0.85–6.54)
rs12979860 TT/CT 48 22.9 1 0.060
CC 52 40.4 3.55 (0.95–5.45)
HBV, hepatits B virus; HCV, hepatitis C virus; HBc, hepatitis B core; HBsAG, Hepatitis B surface Antigen; IL28B, Interleukin 28B.
doi:10.1371/journal.pone.0027555.t002
Figure 1. Distribution of sex for each genotype plotted by
spontaneous HCV clearance rate. Genotyping was available for
100/106 participants. Bars represent the total percentage of spontane-
ous HCV clearance for the protective alleles (TT for rs8099917 and CC
for rs12979860) and non-protective alleles (CT/GG for rs8099917 and
CT/TT for rs12979860). The numbers in the bars indicate the percentage
of spontaneous HCV clearance for males and females for each allele.
doi:10.1371/journal.pone.0027555.g001
Table 3. Multivariate analysis of factors associated with HCV
clearance in a cohort of 106 individuals with acute HCV
acquired through injection drug use.
OR 95% CI P value
Sex*rs12979860 Male, TT/CT 1 0.021
Male, CC 1.34 0.37–4.85
Female, TT/CT 1.14 0.28–4.76
Female, CC 6.62 2.69–26.13
Fever No 1 0.023
Yes 5.03 1.24–20.33
doi:10.1371/journal.pone.0027555.t003
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with the unfavorable genotype were as likely as men with the
favorable and unfavorable genotype to clear HCV.
The rate of clearance we found is higher than observed in
studies among acute clinical cases (reviewed by Micallef [30]), but
may be underestimated in injecting DU. Many injecting DU
experience repeated exposure to HCV and HCV re-infection after
their initial HCV seroconversion, due to continuing risk behavior
[28]. Such re-infection after clearance might result in persistent or
recurrent HCV viremia, leading to an underestimation of the
clearance rate. However, in this cohort of DU with acute HCV,
we did not find an association between ongoing risk behavior and
reduced rates of viral clearance shortly after the initial HCV
infection.
Studies have suggested that individuals presenting with clinical
symptoms after exposure to HCV after needle-stick injury or
presenting at an outpatient clinic are more likely to spontaneously
resolve acute HCV infection [7,31]. Self-reported fever was
associated with HCV viral clearance in this cohort of DU, other
clinical symptoms were not.
The association between HCV clearance and absence of HIV
was borderline. HIV infection has been associated with loss of viral
control of HCV, as evidenced by a higher HCV viral load in
HIV co-infected individuals [32]. Since HCV is more efficiently
transmitted by an infected needle stick than HIV, HCV usually
precedes or coincides with HIV infection in DU. Therefore, the
number of participants with HIV at HCV seroconversion was
small, limiting the power to detect an effect. In addition, therefore
all HIV co-infected DU in our study retained high CD4 counts at
the point of HCV infection. This might explain why HCV viral
load did not significantly differ between co-infected and mono-
infected individuals in our study. As in line with our findings that
early HIV infection already lowers the HCV clearance rate. We
and others have shown that acute HIV co-infection hampers the
beneficial HCV-specific CD4
+ T-cell responses targeting non-
structural proteins in DU [33–37].
Interestingly, chronic HBV was borderline significantly associ-
ated with HCV clearance in the multivariate model, while cases
were limited. Patients with spontaneous viral clearance of chronic
HCV after HBV-superinfection have been described [38], and
cross-sectional studies have shown that HBsAg-positive HIV-
infected HCV-seropositive individuals are more likely to be HCV-
RNA-negative than HBsAg-negative HIV-infected individuals
[39–41]. Although the effect on liver disease is unknown, chronic
HBV infection seems to favor clearance of acute HCV infection
[42]. Further studies on viral interference including the role of
HBV, which may modify HCV replication are warranted.
Having defined viral clearance as two consecutive HCV-RNA-
negative visits after anti-HCV seroconversion, we defined HCV
viral persistence as the continuous presence of HCV RNA at one
or two of these visits, regardless of HCV strain present. Therefore,
we did not distinguish between viral persistence of one strain and
reinfection by another. Furthermore, although HCV clearance is
believed to take place within the first 6 months after acute
infection, evidence shows that clearance might take much longer
[10,43]. Since we included HCV RNA measurements only in the
first 2 years after HCV seroconversion, we recognize that multiple
measurements in a longer time span would be necessary to
evaluate possible late clearance and its predictors. In our cohort,
after a median follow-up after HCV seroconversion of 14.6 years
(IQR 7.9–19.6), only 5 out of 71 (7.0%) individuals who did not
clear HCV spontaneously within the first 2 years after HCV
seroconversion were HCV RNA-negative at the last study visit,
without HCV treatment in the meantime, before November 2005
or the penultimate visit preceding death, indicating that late
clearance might occur, but is not very frequent (data not shown).
Our main finding is the potential interaction between the
favourable genotype of rs12989760 and women in spontaneous
clearance of HCV. However, since our study population is
relatively small, this finding needs to be confirmed in larger
studies among HCV seroconverters. A possible interaction
between IL28B and sex in HCV fibrosis progression has been
described previously by Falletti et al. [44] This retrospective study
among 629 cHCV infected patients investigated the role of IL28B
on the histological outcome of cHCV infection. One of their
findings is that males carrying the favourable C-allele for
rs12979860 had a significant increased risk (OR 2.06) for an
Ishak staging score .2 as compared to females with the favourable
C-allele (reference category), while participants carrying the TT
genotype also had an increased risk (OR 2.37) for an Ishak
score.2, irrespective of sex.
The potential interaction between female gender and Il28B
might be explained by the involvement of toll like receptor 7
(TLR7), a receptor that is involved in recognition of viral products
(single stranded RNA) and activation of innate immunity [45].
Stimulation of TLR7 in peripheral blood mononuclear cells
(PBMC) from women results in significantly higher IFN-a
responses as compared to males [46]. The TLR7 activation signal
is transduced via MyD88 to the IL-1R-associated kinase 1/4
complex that activates interferon regulatory factor 7 (IRF7).
Recently, it has been demonstrated that IL28B (IFN-l) is mainly
controlled by IRF7 [47]. Interestingly, IFN-l mediates its antiviral
activity through the activation of JAK-STAT pathways, similar to
IFN-a which is still the major treatment modality for cHCV
infection, thereby inducing interferon stimulating genes (ISG) that
suppress viral activity. Marcello et al showed, in vitro, that co
treatment with both IFN-a and IFN-l enhanced the antiviral
activity, suggestive of a synergistic interaction [48]. Whether
increased reactivity upon TLR7 stimulation results in both
increased IFN-a and IFN-l responses needs to be investigated.
Next to the relatively small sample size, our study is limited by
the fact that variables on behaviour and symptoms are self-
reported, including initiation of injecting drug use for those that
entered our cohort as anti-HCV positive cases. We believed that
we could minimize this bias by only including IDU who started
injecting within two years before inclusion into the study. In an
earlier report, we have shown that approximately 50% of IDU in
the ACS become infected with HCV within two years after
initiating injecting drug use and self-reports are valid [26,49]. In
addition, in a sensitivity analysis including only HCV seroconver-
ters with a small interval between last anti-HCV negative and first
anti-HCV positive test, results were comparable.
In conclusion, women with the favorable CC genotype for
rs12979860 have the greatest likelihood to spontaneously resolve
HCV. The decision to start HCV treatment might be postponed
in this group, if not coinfected with HIV. Spontaneous clearance
of HCV seems to be primarily driven by host genetic factors and
presence of coinfection. The possible synergistic interaction
between female sex and the favorable genotype warrants
confirmation in larger studies and warrants further study into
the immunological and virological mechanisms explaining this
finding.
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